Login & Signup

  • PreIPO
  • Startup Fund Raising
  • Valuations
  • Equity Restructing

  • Investments
  • Mutual Funds
  • Demat Account
  • Bonds/NCD
  • Insurance
  • Life Insurance
  • Health Insurance
  • Car Insurance
  • Corporates & Business
  • Property Insurance
  • Group Health Insurance
  • Marine Insurance
  • Important update for Pharmeasy investors

    18 November

After a horrendous start of Paytm, we are again cautioning investors on Pharmeasy.


Pharmeasy Consolidated Results (including all subsidiaries) as per March,2021

Total Revenue => ₹4,363.2 cr 

Total Consolidated Loss (including all subsidiaries) => ₹1,548.5 cr

Total Debt on 30th June,2021 => ₹2,772.61 cr


This means on every 1 cr sale of medicine, lab tests (including all subsidiaries), company incur a loss of 35.49 Lacs.


People should be cautious while investing in Pharmeasy stocks at such steep valuations or exit before the stock crashes.